A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
A pharmacokinetic (PK) model was developed for nusinersen, an antisense oligonucleotide (ASO) that is the first approved treatment for spinal muscular atrophy (SMA). The model was built with data from 92 nonhuman primates (NHPs) following intrathecal doses (0.3-7 mg) and characterized the PK in cere...
Saved in:
Main Authors: | Konstantinos Biliouris (Author), Puneet Gaitonde (Author), Wei Yin (Author), Daniel A. Norris (Author), Yanfeng Wang (Author), Scott Henry (Author), Robert Fey (Author), Ivan Nestorov (Author), Stephan Schmidt (Author), Mark Rogge (Author), Lawrence J. Lesko (Author), Mirjam N. Trame (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2018-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen
by: Alessio Paris, et al.
Published: (2023) -
Mechanistic insights into ASO-RNA complexation: Advancing antisense oligonucleotide design strategies
by: Johanna Hörberg, et al.
Published: (2024) -
Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
by: Haiyan Zhou, et al.
Published: (2020) -
A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy
by: Jeffrey M Keil, et al.
Published: (2014) -
Tissue pharmacokinetics of antisense oligonucleotides
by: Erica Bäckström, et al.
Published: (2024)